Table 3.
Adverse events.
| Adverse events | BCG n (%) | Gemcitabine n (%) | p-Value |
|---|---|---|---|
| Cystitis | 6 (11%) | 2 (3%) | 0.14 |
| Urosepsis | 5 (9%) | 0 | 0.06 |
| Suprapubic discomfort | 3 (5%) | 2 (3%) | 0.66 |
| Hematuria | 5 (9%) | 0 | 0.06 |
| Systemic BCG infection | 4 (7%) | 0 | 0.11 |
| Total | 23 (44%) | 4 (7%) | <0.05 |
GEM, intravesical gemcitabine; BCG, intravesical bacillus Calmette–Guérin.